Skip to main content

Beam Therapeutics Inc 10-Q for FY2026 Q3

Beam Therapeutics Inc. (BEAM)

10-Q 2026-11-03 For: 2026-09-30
View Original
Added on November 03, 2026

About this 10-Q

Beam Therapeutics Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Beam Therapeutics plans to submit a biologics license application (BLA) for risto-cel as early as year-end 2026, after completing dosing for all adult and adolescent patients in its BEACON trial. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$307K
down 96.8% from $9.7M a year earlier
Net loss
$134.41M
compared with a net loss of $112.57M a year earlier
Diluted EPS
-$1.28
compared with -$1.10 a year earlier